Press Releases

London, England, May 25, 2024 (GLOBE NEWSWIRE) --

During a recent industry conference, Adam Carl Waldman, CEO of ValueZone, detailed the strategies that have positioned ValueZone as one of the best crypto  trading platforms in the cryptocurrency market. Aimed at fostering sustainable growth and enhancing user satisfaction, these strategies underscore ValueZone's commitment to maintaining its status as a leader in the trading industry.

Growth-Driven Strategies... (continue reading...)

DALLAS--(BUSINESS WIRE)-- For any wine collector or connoisseur, one of the essential features of their home or business is a well-constructed, luxury wine cellar. THE TASTE OF AMBIANCE: Luxury Wine Cellar Designs by Al Fuentes — president of Dragon Cellars and ret. US Air Force captain (Brown Books Publishing Group; on sale May 21, 2024) — is an exquisitely photographed coffee table book. The full-color pages and photographs showcase over seventeen years... (continue reading...)

Seoul, South Korea, May 25, 2024 (GLOBE NEWSWIRE) -- Marine Moguls has officially launched on the revolutionary ERC-404 protocol, ushering in a new era of digital asset innovation. 

With ~$2.9 Million in prizes attached to over 25% of the tokens, $MOGUL owners have a better than 1 in 4 chance of landing prizes like 100,000 USDT, 50,000 USDT, very generous staking APY, and more. 

$MOGUL Contract: 0x0c9bb15b32334bDAA7Ad319FA356Dd3E8e184564NFT... (continue reading...)

London, England, May 25, 2024 (GLOBE NEWSWIRE) -- Crydit, with the vision of “Pay Everything,” announces the official launch of the first Unlimited Crypto Card in the industry. Crydit is poised to revolutionize the crypto payment industry, providing users of cryptocurrencies with a free, secure, and convenient payment experience. 

Key Features of the Crydit Unlimited Crypto Card to tell you “WHY CRYDIT”:

Addressing Industry Pain... (continue reading...)

82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n=2/10) who received placebo, and patients treated with felzartamab showed reductions in disease-linked biomarkers and stabilization of eGFR

63% (n=7/11) of felzartamab-treated patients achieved microvascular inflammation (MVI) score of 0 and 100% (n=11/11) of felzartamab treated patients had an improvement in MVI score

... (continue reading...)